Academic Journal
Q1Blood Cancer Journal
About Blood Cancer Journal
Blood Cancer Journal is a scholarly journal published by Springer Nature. SCImago 2025 lists it in Q1, with an SJR of 4.307 and H-index of 94.
Coverage: 2011-2026. Research categories: Hematology (Q1); Oncology (Q1).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-03-17. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Multiple Myeloma Research and Treatments; Acute Myeloid Leukemia Research; Lymphoma Diagnosis and Treatment; Chronic Lymphocytic Leukemia Research; Myeloproliferative Neoplasms: Diagnosis and Treatment; Protein Degradation and Inhibitors.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Bridging therapy response and type as determinants of cilta-cel outcomes in relapsed/refractory multiple myeloma
Doris K. Hansen, Brett M. Reid, Ariel Grajales-Cruz, Peter Cheng et al.
2026-10-01 · DOI: 10.1038/s41408-026-01633-5Early post-transplant molecular residual disease predicts outcomes in myelodysplastic neoplasms/syndromes and acute myeloid leukemia undergoing allogeneic transplantation
Wan-Hsuan Lee, Xavier Cheng-Hong Tsai, Chien-Chin Lin, Feng-Ming Tien et al.
2026-10-01 · DOI: 10.1038/s41408-026-01637-1Infection risk and management in patients with relapsed/refractory multiple myeloma treated with linvoseltamab in the LINKER-MM1 study
Joshua Richter, Madhav Dhodapkar, Mansi R. Shah, Joaquín Martinez-Lopez et al.
2026-10-01 · DOI: 10.1038/s41408-026-01636-2Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia
Abiola Bolarinwa, Muhammad Yousuf, Aref Al-Kali, Hassan B. Alkhateeb et al.
2026-09-30 · DOI: 10.1038/s41408-026-01615-7Real-world treatment patterns and outcomes of brentuximab vedotin–based therapy in CD30-positive lymphomas in China: the prospective BRAVE study
Ming-Ci Cai, Ou Bai, Hui-Lai Zhang, Chuan-Xu Liu et al.
2026-09-30 · DOI: 10.1038/s41408-026-01627-3Redefining the role of second transplantation in adult ALL with post-transplant relapse in the modern era of immuno-targeted therapies
Jaehyun Ahn, Daehun Kwag, Gi June Min, Sung-Soo Park et al.
2026-09-30 · DOI: 10.1038/s41408-026-01628-2High MECOM protein levels confer adverse prognosis in acute myeloid leukemia independent of Chromosome 3 abnormalities
Steven M. Kornblau, Eduardo Sabino de Camargo Magalhães, Brandon D. Brown, Samanta Soledad Catueno et al.
2026-09-30 · DOI: 10.1038/s41408-026-01629-1End-of-induction circulating tumor DNA outperforms conventional cellular MRD for predicting early progression in follicular lymphoma: an ancillary study of the RELEVANCE randomized trial
Alexis Claudel, Pierre-Julien Viailly, Pierre Feugier, Cedric Rossi et al.
2026-09-29 · DOI: 10.1038/s41408-026-01631-7Hypogammaglobulinemia, neutropenia, and lymphopenia, and risk for infection and mortality in patients following daratumumab for multiple myeloma
Joseph S. Hong, Lingxiao Zhang, Baijun Zhou, Katherine J. Liu et al.
2026-09-28 · DOI: 10.1038/s41408-026-01626-4Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia
Paul J. Hampel, Ying Huang, John N. Allan, Seema A. Bhat et al.
2026-09-26 · DOI: 10.1038/s41408-026-01622-8Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study
Oren Pasvolsky, Bruno Almeida Costa, Yosra M. Aljawai, Krina K. Patel et al.
2026-09-26 · DOI: 10.1038/s41408-026-01620-wClinical, cytogenetic, and germline genetic determinants of arterial thromboembolism in IMiD-treated multiple myeloma
Sina A. Beer, David A. Cairns, Molly Went, Philip Law et al.
2026-09-24 · DOI: 10.1038/s41408-026-01635-3Comparative efficacy and safety of CD19 chimeric antigen receptor T-cell therapy versus CD3/CD20 bispecific antibodies in relapsed/refractory mantle cell lymphoma: a meta-analysis of clinical trials and real-world studies
Julia Wang, Justin Desroches, Fang Yang, Dongni Yi et al.
2026-09-23 · DOI: 10.1038/s41408-026-01624-6The mutational landscape of resistance to BTK and BCL2 inhibitors in CLL: a real-world multicentric study
Miguel Bastos-Boente, María García-Álvarez, Cristina Jiménez, Alicia Antón et al.
2026-09-22 · DOI: 10.1038/s41408-026-01619-3Long-term survival and cause-specific mortality after event-free survival at 24 months (EFS24) in mantle cell lymphoma: an international multicohort study
Yucai Wang, Melissa C. Larson, Umar Farooq, Sara Ekberg et al.
2026-09-22 · DOI: 10.1038/s41408-026-01625-5Stem cell autograft minimal residual disease negativity and survival outcomes for multiple myeloma autotransplant
Noriko Nishimura, Samantha Brown, Sarah Samorodnitsky, Sean M. Devlin et al.
2026-09-22 · DOI: 10.1038/s41408-026-01621-9REVEAL-MM: retrospective evaluation of variables in early assessment and landmark trends in multiple myeloma—a US claims-based case-control study
Faith E. Davies, Beth Faiman, Hayley Beer, Anne Quinn Young et al.
2026-09-14 · DOI: 10.1038/s41408-026-01609-5Safety and efficacy of birelentinib, a novel LYN/BTK dual inhibitor, in relapsed/refractory diffuse large B-cell lymphoma: a phase 2 study (TAI-SHAN9)
Yajun Li, Wei Liu, Keshu Zhou, Wenbing Qian et al.
2026-09-08 · DOI: 10.1038/s41408-026-01617-5A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma
Ricardo Ahrens, Kyra Ahrens, Maximilian Al-Bazaz, Lisa Leypoldt et al.
2026-09-03 · DOI: 10.1038/s41408-026-01616-6Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
Doris K. Hansen, Danai Dima, Hira Mian, Jakob Devos et al.
2026-08-31 · DOI: 10.1038/s41408-026-01605-9Reviews
Community Reviews
Version History
October 4, 2026 at 8:43 pm
September 11, 2026